Tumors with BRAF or KRAS mutations were in correlation with elevated serum level of tumor biomarkers of CRC and the combination of serum biomarkers and molecular mutation status may enhance the more precise risk stratification of CRC patients. This evidence concerns the gene BRAF and colorectal carcinoma.